WO2002043659A2 - Composition containing statins and calcium for improved cardiovascular health - Google Patents
Composition containing statins and calcium for improved cardiovascular health Download PDFInfo
- Publication number
- WO2002043659A2 WO2002043659A2 PCT/US2001/044734 US0144734W WO0243659A2 WO 2002043659 A2 WO2002043659 A2 WO 2002043659A2 US 0144734 W US0144734 W US 0144734W WO 0243659 A2 WO0243659 A2 WO 0243659A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- composition
- composition according
- mixture contains
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA03004818A MXPA03004818A (en) | 2000-11-29 | 2001-11-29 | Composition containing statins and calcium for improved cardiovascular health. |
CA002427618A CA2427618A1 (en) | 2000-11-29 | 2001-11-29 | Composition containing statins and calcium for improved cardiovascular health |
US10/433,036 US20040018248A1 (en) | 2001-11-29 | 2001-11-29 | Composition containing statins and calcium for improved cardiovascular health |
AU3651102A AU3651102A (en) | 2000-11-29 | 2001-11-29 | Composition containing statins and calcium for improved cardiovascular health |
JP2002545638A JP2004514684A (en) | 2000-11-29 | 2001-11-29 | Composition containing statin and calcium for improving cardiovascular health |
EP01986043A EP1339429A4 (en) | 2000-11-29 | 2001-11-29 | Composition containing statins and calcium for improved cardiovascular health |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25389900P | 2000-11-29 | 2000-11-29 | |
US60/253,899 | 2000-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002043659A2 true WO2002043659A2 (en) | 2002-06-06 |
WO2002043659A3 WO2002043659A3 (en) | 2002-09-06 |
Family
ID=22962156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/044734 WO2002043659A2 (en) | 2000-11-29 | 2001-11-29 | Composition containing statins and calcium for improved cardiovascular health |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1339429A4 (en) |
JP (1) | JP2004514684A (en) |
AU (1) | AU3651102A (en) |
CA (1) | CA2427618A1 (en) |
MX (1) | MXPA03004818A (en) |
WO (1) | WO2002043659A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006919A1 (en) * | 2002-07-11 | 2004-01-22 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocystein |
FR2847472A1 (en) * | 2002-11-22 | 2004-05-28 | Synergia | Pharmaceutical or dietetic compositions useful for protecting against artery and heart disease comprise B vitamins and vitamin C |
JP2004189716A (en) * | 2002-07-11 | 2004-07-08 | Sankyo Co Ltd | Medicinal composition for improving lipid in blood, or reducing homocysteine in blood |
WO2004058281A1 (en) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingedients Gmbh | Cholesterol-reducing agent containing an n-3 fatty acid |
EP1551382A2 (en) * | 2002-09-27 | 2005-07-13 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
EP1558237A2 (en) * | 2002-09-27 | 2005-08-03 | Martek Biosciences Corporation | Improved glycemic control for prediabetes and/or diabetes type ii using docosahexaenoic acid |
WO2006013602A1 (en) * | 2004-08-03 | 2006-02-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition containing statins and omega-3 fatty acids |
WO2006017698A2 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
WO2006021293A1 (en) * | 2004-08-23 | 2006-03-02 | Unilever N.V. | Composition comprising statin |
WO2006045865A1 (en) * | 2004-10-19 | 2006-05-04 | Gp Pharm S.A. | Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
EP1703911A1 (en) * | 2003-12-23 | 2006-09-27 | Medicure International Inc. | Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
EP1922065A2 (en) * | 2005-08-04 | 2008-05-21 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
EP1946755A1 (en) * | 2005-11-11 | 2008-07-23 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
WO2009059717A3 (en) * | 2007-11-08 | 2009-09-03 | Iervant Zarmanian | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use |
WO2010041017A2 (en) * | 2008-10-08 | 2010-04-15 | Ayanda As | Chewable gelled emulsions |
ITFI20080243A1 (en) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | FORMULATIONS FOR ORAL ADMINISTRATION OF OMEGA POLIENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI-SYNTHETIC STATINES. |
WO2011078712A1 (en) | 2009-12-23 | 2011-06-30 | Dafiante Farmacêutica S.A. | Combination composition useful for treating cardiovascular diseases |
WO2012128587A3 (en) * | 2011-03-23 | 2012-11-15 | Hanmi Pharm. Co., Ltd. | Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
WO2012085671A3 (en) * | 2010-12-21 | 2013-04-11 | Omegatri As | Antioxidants in fish oil powder and tablets |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
WO2015000986A1 (en) * | 2013-07-02 | 2015-01-08 | International Nutrition Research Company | Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases |
FR3007987A1 (en) * | 2013-07-02 | 2015-01-09 | Internat Nutrition Res Company | MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND METABOLIC OVERVOLTAGE |
FR3007986A1 (en) * | 2013-07-02 | 2015-01-09 | Internat Nutrition Res Company | MEDICAMENT FOR CONTROLLING INFERTILITY AND SUB-FERTILITY IN PARTICULAR WITHIN METABOLIC FERTILITY OR INFERTILITY |
FR3007985A1 (en) * | 2013-07-02 | 2015-01-09 | Internat Nutrition Res Company | MEDICAMENT FOR THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC RISK FACTORS, IN PARTICULAR CARDIOVASCULAR DISEASES, PRE DIABETES, TYPE II DIABETES AND HEPATIC STEATOSIS |
US9724296B2 (en) | 2008-10-08 | 2017-08-08 | Vitux Group As | Chewable gelled emulsions |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060211762A1 (en) * | 2004-12-06 | 2006-09-21 | Rongen Roelof M | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
EP2081550B2 (en) * | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
KR20110039249A (en) * | 2008-07-07 | 2011-04-15 | 모치다 세이야쿠 가부시키가이샤 | Ameliorating or therapeutic agent for dyslipidemia |
WO2011047259A1 (en) | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Compositions |
AU2016402338A1 (en) * | 2016-04-14 | 2018-11-08 | Michael LUCEY | Combinational compositions and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5886037A (en) * | 1996-11-20 | 1999-03-23 | N.V. Nutricia | Nutritional composition for the treatment of hypertriglyceridaemia and hyperchylomicronaemia |
USRE36520E (en) * | 1986-06-23 | 2000-01-18 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2222278C (en) * | 1995-06-06 | 2008-05-13 | Campbell Soup Company | Mineral supplements for dietetic food |
JP2000508659A (en) * | 1996-04-17 | 2000-07-11 | メルク エンド カンパニー インコーポレーテッド | Combination therapy to reduce cardiovascular disease-related risks |
-
2001
- 2001-11-29 EP EP01986043A patent/EP1339429A4/en not_active Withdrawn
- 2001-11-29 JP JP2002545638A patent/JP2004514684A/en active Pending
- 2001-11-29 AU AU3651102A patent/AU3651102A/en active Pending
- 2001-11-29 CA CA002427618A patent/CA2427618A1/en not_active Abandoned
- 2001-11-29 MX MXPA03004818A patent/MXPA03004818A/en unknown
- 2001-11-29 WO PCT/US2001/044734 patent/WO2002043659A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE36520E (en) * | 1986-06-23 | 2000-01-18 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
US5886037A (en) * | 1996-11-20 | 1999-03-23 | N.V. Nutricia | Nutritional composition for the treatment of hypertriglyceridaemia and hyperchylomicronaemia |
Non-Patent Citations (1)
Title |
---|
See also references of EP1339429A2 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100341509C (en) * | 2002-07-11 | 2007-10-10 | 三共株式会社 | Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
JP2010077162A (en) * | 2002-07-11 | 2010-04-08 | Daiichi Sankyo Co Ltd | Medicinal composition for lowering blood homocysteine |
WO2004006919A1 (en) * | 2002-07-11 | 2004-01-22 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocystein |
JP2004189716A (en) * | 2002-07-11 | 2004-07-08 | Sankyo Co Ltd | Medicinal composition for improving lipid in blood, or reducing homocysteine in blood |
AU2003272738B2 (en) * | 2002-09-27 | 2010-04-01 | Martek Biosciences Corporation | Docosahexaenoic acid for improved glycemic control |
EP2283838A3 (en) * | 2002-09-27 | 2011-04-20 | Martek Biosciences Corporation | Docosahexaenoic acid for treating subclinical inflammation |
EP1558237A2 (en) * | 2002-09-27 | 2005-08-03 | Martek Biosciences Corporation | Improved glycemic control for prediabetes and/or diabetes type ii using docosahexaenoic acid |
EP2283837A3 (en) * | 2002-09-27 | 2011-04-20 | Martek Biosciences Corporation | Docosahexaenoic acid for treating subclinical inflammation |
EP1551382A2 (en) * | 2002-09-27 | 2005-07-13 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
EP1551382A4 (en) * | 2002-09-27 | 2007-01-24 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
EP1558237A4 (en) * | 2002-09-27 | 2007-01-17 | Martek Biosciences Corp | Improved glycemic control for prediabetes and/or diabetes type ii using docosahexaenoic acid |
FR2847472A1 (en) * | 2002-11-22 | 2004-05-28 | Synergia | Pharmaceutical or dietetic compositions useful for protecting against artery and heart disease comprise B vitamins and vitamin C |
WO2004047564A1 (en) * | 2002-11-22 | 2004-06-10 | Synergia Holding | Novel pharmaceutical compositions in particular for preventing cardiovascular pathologies |
WO2004058281A1 (en) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingedients Gmbh | Cholesterol-reducing agent containing an n-3 fatty acid |
EP1703911A4 (en) * | 2003-12-23 | 2009-03-18 | Medicure Int Inc | Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
EP1703911A1 (en) * | 2003-12-23 | 2006-09-27 | Medicure International Inc. | Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
WO2006013602A1 (en) * | 2004-08-03 | 2006-02-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition containing statins and omega-3 fatty acids |
AU2005268402B2 (en) * | 2004-08-03 | 2010-08-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition containing statins and omega-3 fatty acids |
KR101355122B1 (en) * | 2004-08-03 | 2014-02-04 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | Composition containing statins and omega-3 fatty acids |
US8853229B2 (en) | 2004-08-03 | 2014-10-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition containing statins and omega-3 fatty acids |
EA014444B1 (en) * | 2004-08-03 | 2010-12-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Composition containing statins and omega-3 fatty acids |
CN1993119B (en) * | 2004-08-03 | 2011-04-06 | 希格马托制药工业公司 | Composition containing statins and omega-3 fatty acids |
EP1786414A4 (en) * | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | Novel statin pharmaceutical compositions and related methods of treatment |
EP1786414A2 (en) * | 2004-08-06 | 2007-05-23 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
WO2006017698A2 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
US7642287B2 (en) * | 2004-08-06 | 2010-01-05 | Transform Pharmaceuticals, Inc. | Statin pharmaceutical compositions and related methods of treatment |
WO2006021293A1 (en) * | 2004-08-23 | 2006-03-02 | Unilever N.V. | Composition comprising statin |
AU2005276686B2 (en) * | 2004-08-23 | 2008-11-20 | Unilever Plc | Composition comprising statin |
EA012371B1 (en) * | 2004-10-19 | 2009-10-30 | Гп Фарм С.А. | Pharmaceutical formulation comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
KR101413339B1 (en) * | 2004-10-19 | 2014-06-27 | 데피안떼 파마슈띠까 에스.에이. | Pharmaceutical composition comprising microcapsules of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
WO2006045865A1 (en) * | 2004-10-19 | 2006-05-04 | Gp Pharm S.A. | Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
EP1922065A2 (en) * | 2005-08-04 | 2008-05-21 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
EP1922065A4 (en) * | 2005-08-04 | 2009-11-11 | Transform Pharmaceuticals Inc | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
US7772277B2 (en) | 2005-08-04 | 2010-08-10 | Transform Pharmaceuticals, Inc. | Formulations comprising fenofibrate and a statin, and related methods of treatment |
EP1946755A4 (en) * | 2005-11-11 | 2012-12-26 | Mochida Pharm Co Ltd | Jelly composition |
EP1946755A1 (en) * | 2005-11-11 | 2008-07-23 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
WO2009059717A3 (en) * | 2007-11-08 | 2009-09-03 | Iervant Zarmanian | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use |
WO2010041017A2 (en) * | 2008-10-08 | 2010-04-15 | Ayanda As | Chewable gelled emulsions |
WO2010041017A3 (en) * | 2008-10-08 | 2010-06-03 | Ayanda As | Chewable gelled emulsions |
US10668013B2 (en) | 2008-10-08 | 2020-06-02 | Vitux Group As | Chewable gelled emulsions |
US9724296B2 (en) | 2008-10-08 | 2017-08-08 | Vitux Group As | Chewable gelled emulsions |
ITFI20080243A1 (en) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | FORMULATIONS FOR ORAL ADMINISTRATION OF OMEGA POLIENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI-SYNTHETIC STATINES. |
WO2010069951A1 (en) * | 2008-12-15 | 2010-06-24 | Valpharma S.A. | Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins |
WO2011078712A1 (en) | 2009-12-23 | 2011-06-30 | Dafiante Farmacêutica S.A. | Combination composition useful for treating cardiovascular diseases |
WO2012085671A3 (en) * | 2010-12-21 | 2013-04-11 | Omegatri As | Antioxidants in fish oil powder and tablets |
CN103442699A (en) * | 2011-03-23 | 2013-12-11 | 韩美药品株式会社 | Oral complex composition comprising omega-3 fatty acid ester and HMG-CoA reductase inhibitor |
EA023405B1 (en) * | 2011-03-23 | 2016-05-31 | Ханми Фарм. Ко., Лтд. | ORAL COMPLEX COMPOSITION COMPRISING OMEGA-3 FATTY ACID ESTER AND HMG-CoA REDUCTASE INHIBITOR |
WO2012128587A3 (en) * | 2011-03-23 | 2012-11-15 | Hanmi Pharm. Co., Ltd. | Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
WO2015000986A1 (en) * | 2013-07-02 | 2015-01-08 | International Nutrition Research Company | Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases |
FR3007987A1 (en) * | 2013-07-02 | 2015-01-09 | Internat Nutrition Res Company | MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND METABOLIC OVERVOLTAGE |
FR3007986A1 (en) * | 2013-07-02 | 2015-01-09 | Internat Nutrition Res Company | MEDICAMENT FOR CONTROLLING INFERTILITY AND SUB-FERTILITY IN PARTICULAR WITHIN METABOLIC FERTILITY OR INFERTILITY |
FR3007985A1 (en) * | 2013-07-02 | 2015-01-09 | Internat Nutrition Res Company | MEDICAMENT FOR THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC RISK FACTORS, IN PARTICULAR CARDIOVASCULAR DISEASES, PRE DIABETES, TYPE II DIABETES AND HEPATIC STEATOSIS |
Also Published As
Publication number | Publication date |
---|---|
WO2002043659A3 (en) | 2002-09-06 |
MXPA03004818A (en) | 2003-09-10 |
AU3651102A (en) | 2002-06-11 |
JP2004514684A (en) | 2004-05-20 |
CA2427618A1 (en) | 2002-06-06 |
EP1339429A4 (en) | 2007-03-14 |
EP1339429A2 (en) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040018248A1 (en) | Composition containing statins and calcium for improved cardiovascular health | |
WO2002043659A2 (en) | Composition containing statins and calcium for improved cardiovascular health | |
US20060105033A1 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
US8927012B2 (en) | Multi-vitamin and mineral nutritional supplements | |
US5364644A (en) | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders | |
US6020383A (en) | Method for reducing blood cholesterol and/or blood triglycerides | |
WO2000045770A2 (en) | Compressed lecithin preparations | |
EP1054678B1 (en) | Combination of steroid and polyunsaturated fatty acids for treatment of inflammatory conditions | |
JP4986321B2 (en) | Methods and compositions for the treatment of inflammatory conditions | |
KR20130046451A (en) | Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease | |
EP1021087A1 (en) | Serotonin containing formulation for oral administration and method of use | |
US8557236B2 (en) | Cardiovascular support supplement and compositions and methods thereof | |
WO2002043662A2 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
CA2346647C (en) | Treatment of dyspepsia | |
EP1541041B1 (en) | Dietary compositions against stress | |
US9308261B2 (en) | Compositions and methods for treating varicose veins | |
MXPA01007008A (en) | Method for reducing blood cholesterol and/or blood triglycerides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2427618 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002545638 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/004818 Country of ref document: MX Ref document number: 10433036 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001986043 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001986043 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001986043 Country of ref document: EP |